Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACellDream 2: Autologous adipose-derived stromal/stem cells for critical limb ischemia
2018-000967-10Phase 2Completed
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Oct 2018
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adipose derived mesenchymal stromal cells in chronic limb-threatening ischemia (CLTI), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Limb salvage and resolution of critical limb ischemia at 6 months. Started Oct 2018; status: completed.
02
Drugs
adipose derived mesenchymal stromal cells
03
Conditions
chronic limb-threatening ischemia (CLTI)
Beyond the preview
Go deeper on 2018-000967-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000967-10.